Edit with
Fjord Biotech is developing a novel inhaled therapy designed to address respiratory viral infections in vulnerable respiratory patients through local lung delivery — targeting the viral trigger directly while supporting lung health.
Respiratory viruses remain a major driver of hospitalization and disease progression in vulnerable respiratory patients.
Current therapies primarily manage symptoms, while no broadly applicable inhaled antiviral therapy exists today.
For most people, a respiratory virus means a few days of discomfort.
For millions of patients living with chronic respiratory diseases (CRD), the same infection can trigger hospitalization, accelerated disease progression and increased mortality.
people living with chronic respiratory diseases
suffering from one or more flare-ups every year
deaths per year caused by chronic respiratory diseases
estimated flare-ups triggered by viral infections
Current therapies primarily manage symptoms. They help patients breathe easier, reduce inflammation and manage flare-ups.
However, no broad-spectrum antiviral therapy is available for flare-ups.
Fjord Biotech is developing a therapy designed to target the viral trigger directly while supporting lung health through a dual antiviral and anti-inflammatory mechanism.
A targeted inhaled therapeutic approach that delivers active compounds directly to the site of infection — maximising efficacy while minimising systemic exposure.
Broad-spectrum antiviral activity demonstrated across multiple respiratory viruses, including RSV, influenza, rhinovirus and SARS-CoV-2.
Reduce harmful inflammatory responses associated with respiratory infections — protecting lung tissue during and after viral attack.
Produced through industrial fermentation with pharmaceutical-scale manufacturing potential — designed for reliable commercial supply.
Proprietary technology platform with future expansion opportunities across multiple respiratory indications.
Engineered for pharmaceutical development and scalable manufacturing.
Fjord Biotech's technology is based on a proprietary highly sulfated polysaccharide platform produced from a marine-derived biological source through controlled industrial fermentation.
The platform is designed to deliver pharmaceutical-grade reproducibility, scalable manufacturing and consistent biological activity.
Proprietary highly sulfated polysaccharide technology derived from a marine biological source.
Produced through controlled industrial fermentation ensuring batch-to-batch consistency.
Designed for batch-to-batch consistency and pharmaceutical-grade quality standards.
Manufacturing process suitable for future commercial scale-up to meet global patient demand.
Significant progress already achieved — from compound identification through manufacturing process establishment.
Multiple years of R&D completed, establishing a robust scientific foundation.
Antiviral and anti-inflammatory activity observed in relevant studies across multiple respiratory viruses.
Industrial fermentation process developed and scalable to commercial quantities.
Supported by internationally recognized respiratory experts and GOLD committee members.
Fjord Biotech is developing a platform technology with potential applications beyond a single product or indication. The underlying technology combines broad antiviral activity, immune-modulating properties, scalable manufacturing and protected intellectual property.
COPD patients with high risk of viral triggered deterioration — the highest unmet medical need.
Asthma, bronchiectasis and other respiratory indications with significant patient populations.
Broad-spectrum antiviral potential across multiple respiratory viruses beyond the initial indication.
Potential future applications where inflammatory regulation plays an important role in disease management.
The Fjord Biotech team combines deep expertise across the full drug development and commercialization value chain.
"Supported by leading global respiratory experts and translational pharmacologists, including GOLD committee members — the world's foremost authority on COPD management."
We welcome inquiries from investors, pharmaceutical partners, clinical collaborators, and respiratory experts interested in advancing our mission.